Literature DB >> 17459273

Bone metabolism and new targets for intervention.

Bulent Akduman1, E David Crawford.   

Abstract

Bone metastasis is a common complication of prostate cancer and is associated with significant morbidity for patients. Bone metabolism and prostate cancer metastasis to bone are complex processes. The interactions between host cells and metastatic prostate cancer cells are important components of organ-specific cancer progression. In addition to traditional treatment approaches, targeted therapy is currently becoming more popular. Bone metabolism, metastatic processes of prostate cancer, and the targeting of treatment for advanced disease are discussed here.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17459273     DOI： 10.1007/s11934-007-0011-y

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  64 in total

Review 1.  Extracellular matrix remodelling: the role of matrix metalloproteinases.

Authors:  Ivan Stamenkovic
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

2.  The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.

Authors:  Sotaro Miwa; Atsushi Mizokami; Evan T Keller; Russell Taichman; Jian Zhang; Mikio Namiki
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

3.  The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2.

Authors:  Hyun-Jung Kim; Jung-Hwan Kim; Suk-Chul Bae; Je-Yong Choi; Hyun-Jung Kim; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2002-10-25       Impact factor: 5.157

4.  Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones.

Authors:  J Pfeilschifter; G R Mundy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

5.  Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components.

Authors:  C Festuccia; M Bologna; G L Gravina; F Guerra; A Angelucci; I Villanova; D Millimaggi; A Teti
Journal:  Int J Cancer       Date:  1999-05-05       Impact factor: 7.396

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 7.  Role of endothelin-1 in osteoblastic bone metastases.

Authors:  Theresa A Guise; Juan Juan Yin; Khalid S Mohammad
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

8.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

Authors:  A Mizuno; N Amizuka; K Irie; A Murakami; N Fujise; T Kanno; Y Sato; N Nakagawa; H Yasuda; S Mochizuki; T Gomibuchi; K Yano; N Shima; N Washida; E Tsuda; T Morinaga; K Higashio; H Ozawa
Journal:  Biochem Biophys Res Commun       Date:  1998-06-29       Impact factor: 3.575

Review 9.  Osteoblastic metastasis in advanced prostate cancer.

Authors:  M Koutsilieris
Journal:  Anticancer Res       Date:  1993 Mar-Apr       Impact factor: 2.480

10.  Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation.

Authors:  T Ebisawa; K Tada; I Kitajima; K Tojo; T K Sampath; M Kawabata; K Miyazono; T Imamura
Journal:  J Cell Sci       Date:  1999-10       Impact factor: 5.285
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.